Both studies started with 6 weeks of observation to count the number of seizures, then a 6-week titration phase followed by a 13-week maintenance period. Patients continued taking their regular antiepileptic therapy during the studies and were offered enrollment in open-label extension studies after completion of the trials.
Eisai Inc., which is developing perampanel, funded the studies. Dr. French has received research support from Eisai and many other companies manufacturing antiepileptic drugs. Some of her associates in the study also disclosed relationships with Eisai and other companies making antiepileptic drugs.